Halozyme Therapeutics, Inc. provided earnings guidance for the twelve months ended December 31, 2023. The company estimates 2023 revenue will be in the range of $827 million to $832 million, net income will be in the range of $292 million to $297 million and GAAP Diluted EPS will be in the range of $2.18 to $2.21.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.86 USD | +1.41% | +3.30% | +7.49% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.49% | 4.99B | |
-0.76% | 104B | |
+5.88% | 97.47B | |
+5.71% | 22.25B | |
-13.10% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-9.89% | 16.36B | |
+8.49% | 14.39B | |
+39.71% | 12.37B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023